Telmisartan versus amlodipine in patients with concurrent type 2 diabetes mellitus and hypertension: Comparing efficacy in terms of insulin resistance and lipid profile
KASAV INTERNATIONAL JOURNAL OF HEALTH SCIENCES · 2024
DOI: 10.29228/kijhs.76358 ↗Kurz gefasst
Fachartikel in der Zeitschrift KASAV INTERNATIONAL JOURNAL OF HEALTH SCIENCES, 2024. Verfasst von Deniz Yılmaz.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND:To explore the impact of telmisartan versus amlodipine on insulin resistance, this study aims to measure the homeostasis model assessment ratio of insulin resistance (HOMA-IR) and assess other diabetes-related variables, lipid parameters, and adiponectin levels.The study group involves patients presenting with both grade I or II essential hypertension and type 2 diabetes mellitus (T2DM).MATERIAL AND METHODS: Conducted between November 2005 and March 2006, this prospective cohort study enrolled patients with type 2 diabetes mellitus (T2DM) and newly-diagnosed essential hypertension.The participants received either telmisartan or amlodipine treatment.Various parameters, including height, weight, blood pressure, and laboratory
Zitieren
APA
Yılmaz, D. (2024). Telmisartan versus amlodipine in patients with concurrent type 2 diabetes mellitus and hypertension: Comparing efficacy in terms of insulin resistance and lipid profile. KASAV INTERNATIONAL JOURNAL OF HEALTH SCIENCES. https://doi.org/10.29228/kijhs.76358
Vancouver
Yılmaz D. Telmisartan versus amlodipine in patients with concurrent type 2 diabetes mellitus and hypertension: Comparing efficacy in terms of insulin resistance and lipid profile. KASAV INTERNATIONAL JOURNAL OF HEALTH SCIENCES. 2024. doi:10.29228/kijhs.76358
BibTeX
@article{Ylmaz2024,
author = {Yılmaz, Deniz},
title = {Telmisartan versus amlodipine in patients with concurrent type 2 diabetes mellitus and hypertension: Comparing efficacy in terms of insulin resistance and lipid profile},
journal = {KASAV INTERNATIONAL JOURNAL OF HEALTH SCIENCES},
year = {2024},
doi = {10.29228/kijhs.76358}
}
EUVIMED